Nektar Therapeutics (NKTR) Other Operating Expenses (2010 - 2025)
Nektar Therapeutics (NKTR) posted quarterly Other Operating Expenses of -$43.3 million for Q2 2025, up 3.12% year-over-year from -$42.0 million in Q2 2024, and up 14.33% quarter-over-quarter from -$50.5 million in Q1 2025.
Nektar Therapeutics (NKTR) Other Operating Expenses (2010 - 2025) Analysis & Trends
Nektar Therapeutics' Other Operating Expenses history runs 16 years deep, the most recent figure standing at -$43.3 million for Q2 2025.
- In Q2 2025, Other Operating Expenses rose 3.12% year-over-year to -$43.3 million; the TTM figure through Mar 2026 stood at -$43.3 million (up 87.36% YoY), while the FY2024 annual figure was -$175.9 million, down 13432.46% from the prior year.
- Other Operating Expenses for Q2 2025 stood at -$43.3 million, up from -$50.5 million in the prior quarter.
- The five-year high for Other Operating Expenses was $103.2 million in Q1 2023, with the low at -$198.6 million in Q4 2024.
- The 5-year median for Other Operating Expenses is $5.3 million (2021), against an average of -$18.6 million.
- Peak annual rise in Other Operating Expenses reached 1840.85% in 2023, while the deepest fall reached 2556.73% in 2023.
- Nektar Therapeutics' Other Operating Expenses stood at $6.2 million in 2021, then gained by 1.14% to $6.2 million in 2022, then sank by 2556.73% to -$153.1 million in 2023, then decreased by 29.72% to -$198.6 million in 2024, then surged by 78.21% to -$43.3 million in 2025.
- Business Quant data shows NKTR's Other Operating Expenses at -$43.3 million in Q2 2025, -$50.5 million in Q1 2025, and -$198.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -43.29 Mn |
| Mar 31, 2025 | -50.53 Mn |
| Dec 31, 2024 | -198.63 Mn |
| Sep 30, 2024 | -48.66 Mn |
| Jun 30, 2024 | -44.69 Mn |
| Mar 31, 2024 | 8.53 Mn |
| Dec 31, 2023 | -153.13 Mn |
| Sep 30, 2023 | 23.26 Mn |
| Jun 30, 2023 | 22.19 Mn |
| Mar 31, 2023 | 103.16 Mn |
| Dec 31, 2022 | 6.23 Mn |
| Sep 30, 2022 | 4.97 Mn |
| Jun 30, 2022 | 5.12 Mn |
| Mar 31, 2022 | 5.32 Mn |
| Dec 31, 2021 | 6.16 Mn |
| Sep 30, 2021 | 5.31 Mn |
| Jun 30, 2021 | 7.67 Mn |
| Mar 31, 2021 | 5.76 Mn |
| Dec 31, 2020 | 4.32 Mn |
| Sep 30, 2020 | 5.57 Mn |